Diet rich in Omega-3 and low in Omega-6 fatty acids helps reduce migraine headaches: BMJ

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-08-06 05:30 GMT   |   Update On 2021-08-06 05:37 GMT

Dietary alteration of Omega-3 and Omega-6 fatty acids help achieve biological impact as well as reduces the frequency and severity of migraine headaches but fails to improve the quality of life in patients, suggests a study published in the BMJ.In the instant study, researchers evaluated the effect of different levels of dietary omega-3 and omega-6 fatty acids on migraine. While Omega-3...

Login or Register to read the full article

Dietary alteration of Omega-3 and Omega-6 fatty acids help achieve biological impact as well as reduces the frequency and severity of migraine headaches but fails to improve the quality of life in patients, suggests a study published in the BMJ.

In the instant study, researchers evaluated the effect of different levels of dietary omega-3 and omega-6 fatty acids on migraine. While Omega-3 fatty acids are thought to be anti-inflammatory and anti-nociceptive, omega-6 fatty acids are pro-inflammatory.The study was conducted by a group of researchers from U.S.A to determine whether dietary interventions that increase Omega-3 fatty acids with and without reduction in Omega-6 linoleic acid can alter circulating lipid mediators implicated in headache pathogenesis, and decrease headache in adults with migraine.

The researchers a total of 182 participants with migraines on 5-20 days per month. Following which they performed a three-arm, parallel-group, randomized, modified double-blind, controlled trial in the academic medical center in the United States for over 16 weeks.

All participants received foods accounting for two-thirds of daily food energy and continued usual care. The authors designed three diets designed with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and linoleic acid altered as controlled variables:

  • H3 diet (n=61)—increase EPA+DHA to 1.5 g/day and maintain linoleic acid at around 7% of energy
  • H3-L6 diet (n=61)—increase n-3 EPA+DHA to 1.5 g/day and decrease linoleic acid to ≤1.8% of energy
  • The Control diet (n=60)—maintain EPA+DHA at <150 mg/day and linoleic acid at around 7% of energy.

The primary endpoints (week 16) were the antinociceptive mediator 17-hydroxydocosahexaenoic acid (17-HDHA) in blood and the headache impact test (HIT-6), a six-item questionnaire assessing headache impact on quality of life.

The results of the study are as follows:

  • In intention-to-treat analyses the H3-L6 and H3 diets increased circulating 17-HDHA (log ng/mL) compared with the control diet.
  • The observed improvement in HIT-6 scores in the H3-L6 and H3 groups were not statistically significant.
  • Compared with the control diet, the H3-L6 and H3 diets decreased total headache hours per day moderate to severe headache hours per day, and headache days per month.
  • The H3-L6 diet decreased headache days per month more than the H3 diet, suggesting an additional benefit from lowering dietary linoleic acid.
  • The H3-L6 and H3 diets altered n-3 and n-6 fatty acids and several of their nociceptive oxylipin derivatives in plasma, serum, erythrocytes, or immune cells, but did not alter classic headache mediator's calcitonin gene-related peptide and prostaglandin E2.

Thus, the researchers concluded that the H3-L6 and H3 interventions altered bioactive mediators implicated in headache pathogenesis and decreased frequency and severity of headaches, but did not significantly improve quality of life.

Reference:

Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: a randomized controlled trial

DOI: https://doi.org/10.1136/bmj.n1448


Tags:    
Article Source : The BMJ

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News